BOSTON, Nov. 2 /PRNewswire/ -- Surface Logix Inc. announced today that
the Company's lead clinical candidate, SLx-2101, has been selected as one
of the top ten most promising cardiovascular drugs in development, offering
significant potential for strategic partnering. SLx-2101 is an oral
selective, fast-onset, long-acting (48 hour) PDE-5 inhibitor designed
specifically to expand the therapeutic potential of PDE-5 inhibition beyond
erectile dysfunction into larger cardiovascular markets. The selection was
made by an independent committee assembled by Windhover Information, a
leading provider of business information products and services to senior
executives in the pharmaceutical, biotechnology, and medical device
industries.
"Selected companies have been screened using a strict set of judging
criteria for the top ten award, and represent what our committee considered
the most attractive cardiovascular licensing opportunities the industry has
to offer," stated Roger Longman of Windhover Information.
"It is an honor to be chosen by this respected group of industry
professionals, and we welcome the independent validation of SLx-2101," said
Jim Mahoney, Surface Logix President and Chief Executive Officer. "We are
currently investigating SLx-2101 in Phase II clinical trials and believe it
will fulfill the original promise of PDE5 inhibition in cardiovascular
disease including hypertension and Raynaud's disease."
The selection committee was led by Marc Wortman, PhD, contributing
writer to Windhover's In Vivo and Start Up, and Ed Saltzman, president of
Defined Health, a leading business development strategy consulting firm.
Drawing on the analytic resources of both organizations, the group
evaluated hundreds of compounds currently in development for the treatment
of cardiovascular disease prior to selecting SLx-2101 among the top ten
most attractive.
The evaluation which ranked SLx-2101 among this top echelon measured a
number of factors including:
-- Unmet medical need
-- Market potential
-- Multi-level partnering opportunities (biotech and pharma)
-- Potential for new opportunities beyond initial indications
-- Diversity of indications
-- History of the molecule and drug
-- Strong science
-- Strong company
As a selected company, Surface Logix has been invited to present data
on SLx-2101 at Windhover's Therapeutic Alliances Cardiovascular Conference
in Chicago on November 16th, immediately following the American Heart
Association (AHA) Conference.
About SLx-2101
SLx-2101 was designed using Surface Logix's proprietary chemistry
platform, the Pharmacomer Technology Platform to have a combination of
potency, selectivity, tissue distribution and half-life which optimizes its
potential for once daily utility in the vascular tissues involved in major
cardiovascular diseases. The clinical experience of SLx-2101 to date
establishes the PK range of the PDE5 inhibitor as well as demonstrating
efficacy in established models of endothelial function (peripheral arterial
tone and erectile function). Additional Phase II studies in cardiovascular
indications are scheduled for Q4, 2006.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
Warwick Tong
Senior Vice President, Commercial Development
wtong@surfacelogix.com
617.746.8500
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Warwick Tong, Senior Vice President,
Commercial Development of +1-617-746-8500,
wtong@surfacelogix.com; or Media: Kari Watson of MacDougall
Biomedical Communications Inc., +1-508-647-0209,
kwatson@macbiocom.com
|
